X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11) 11
pharmacology & pharmacy (9) 9
chemotherapy (7) 7
humans (7) 7
oncology (7) 7
pharmacokinetics (7) 7
pharmacology/toxicology (6) 6
poly polymerase (6) 6
tumors (6) 6
adult (5) 5
female (5) 5
medicine & public health (5) 5
middle aged (5) 5
veliparib (5) 5
aged (4) 4
analysis (4) 4
antineoplastic agents - pharmacokinetics (4) 4
bioavailability (4) 4
abt-888 (3) 3
aged, 80 and over (3) 3
animals (3) 3
benzimidazoles - administration & dosage (3) 3
benzimidazoles - pharmacokinetics (3) 3
breast cancer (3) 3
cancer research (3) 3
cancer therapies (3) 3
combination (3) 3
cross-over studies (3) 3
human necessities (3) 3
hygiene (3) 3
inhibitor (3) 3
male (3) 3
medical or veterinary science (3) 3
monosaccharides (3) 3
nausea (3) 3
neoplasms - drug therapy (3) 3
original (3) 3
original article (3) 3
ovarian neoplasms - drug therapy (3) 3
pharmacology (3) 3
preparations for medical, dental, or toilet purposes (3) 3
specific therapeutic activity of chemical compounds ormedicinal preparations (3) 3
sugars (3) 3
anemia (2) 2
angiogenesis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
benzimidazoles - adverse effects (2) 2
biological availability (2) 2
body weight (2) 2
brain neoplasms - drug therapy (2) 2
breast (2) 2
cancer (2) 2
carboplatin (2) 2
care and treatment (2) 2
chemistry, multidisciplinary (2) 2
clinical research (2) 2
clinical trials (2) 2
deoxyribonucleic acid--dna (2) 2
disease-free survival (2) 2
disposition (2) 2
dna repair (2) 2
dna-repair (2) 2
dose-response relationship, drug (2) 2
drug (2) 2
drug dosages (2) 2
drug evaluation, preclinical (2) 2
efficacy (2) 2
enzymes (2) 2
food effect (2) 2
food-drug interactions (2) 2
internal medicine (2) 2
japanese (2) 2
kinetics (2) 2
lung cancer (2) 2
maximum tolerated dose (2) 2
metastasis (2) 2
mice (2) 2
mutation (2) 2
neutropenia (2) 2
olaparib maintenance therapy (2) 2
original articles (2) 2
ovarian cancer (2) 2
paclitaxel (2) 2
pharmaceuticals (2) 2
pharmacotherapy (2) 2
poly polymerase inhibitors - pharmacokinetics (2) 2
research (2) 2
ribose (2) 2
solid tumors (2) 2
studies (2) 2
sulfonamides - pharmacokinetics (2) 2
temozolomide (2) 2
toxicity (2) 2
trial (2) 2
womens health (2) 2
absorption (1) 1
abt-767 (1) 1
adp (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacokinetics, ISSN 0312-5963, 01/2018, Volume 57, Issue 1, pp. 51 - 58
Background and Objectives Veliparib is an orally active potent poly(ADP-ribose) polymerase (PARP) inhibitor currently in phase III clinical trials in solid... 
POLY(ADP-RIBOSE) POLYMERASE | POLYMERASE PARP INHIBITOR | EFFICACY | IN-VIVO | ABT-888 | CONTINUAL REASSESSMENT METHOD | PHARMACOLOGY & PHARMACY | DNA-REPAIR | DRUG-DRUG INTERACTIONS | CHEMOTHERAPY | DISPOSITION
Journal Article
Cancer Science, ISSN 1347-9032, 11/2017, Volume 108, Issue 11, pp. 2213 - 2220
This phase 1, open‐label, dose‐escalation study was conducted to determine the safety, tolerability, pharmacokinetics and preliminary efficacy of veliparib... 
veliparib | phase I | poly(ADP‐ribose) polymerase inhibitors | ovarian cancer | Japanese | poly(ADP-ribose) polymerase inhibitors | POLY(ADP-RIBOSE) POLYMERASE | ADVANCED SOLID TUMORS | BEVACIZUMAB | PLATINUM | OPEN-LABEL | STAGE-III | COMBINATION | OLAPARIB MAINTENANCE THERAPY | CELL LUNG-CANCER | TRIAL | ONCOLOGY | Drug Administration Schedule | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols | Benzimidazoles - pharmacokinetics | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Carboplatin - pharmacokinetics | Paclitaxel - pharmacokinetics | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Disease-Free Survival | Maximum Tolerated Dose | Benzimidazoles - administration & dosage | Adult | Female | Aged | Benzimidazoles - adverse effects | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Antimitotic agents | Cancer patients | Anemia | Analysis | Oncology, Experimental | Clinical trials | Research | Antineoplastic agents | Sugars | Monosaccharides | Ovarian cancer | Cancer | Hypothesis testing | Enrollments | Lung cancer | Nausea | Neuropathy | Patients | Cancer therapies | Studies | Chemotherapy | Alopecia | Womens health | Response rates | Paclitaxel | Carboplatin | Myelosuppression | Pharmacokinetics | Drug dosages | Neutropenia | Pharmaceuticals | Index Medicus | Original
Journal Article
Cancer Science, ISSN 1347-9032, 09/2017, Volume 108, Issue 9, pp. 1834 - 1842
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2019, Volume 84, Issue 5, pp. 977 - 986
Veliparib, a poly(ADP-ribose)-polymerase (PARP) 1 and 2 enzyme inhibitor, was administered at 120 mg twice daily (BID) for 7 days in a 21-day cycle with... 
Medicine & Public Health | Veliparib | Exposure–response | Paclitaxel | Carboplatin | Oncology | Cancer Research | Breast cancer | Pharmacology/Toxicology | Creatinine | Thrombocytopenia | Effectiveness | Hematology | Leukopenia | Anemia | Toxicity | Body weight | Poly(ADP-ribose) | Poly(ADP-ribose) polymerase | Exposure | Metastasis | ADP | Metastases | Polymerase | Enzyme inhibitors | Ribose | Breast | Safety | Neutropenia
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 08/2018, Volume 57, Issue 8, pp. 901 - 909
Investigating the effect of food on bioavailability during the development of an oral drug product is of prime importance because it has major implications on... 
PHARMACOLOGY & PHARMACY | BIOEQUIVALENCE | ABSORPTION | PHARMACOKINETICS | PRODUCTS | BIOAVAILABILITY
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2017, Volume 79, Issue 3, pp. 587 - 594
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2016, Volume 78, Issue 5, pp. 1003 - 1011
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 3924 - 3924
Background: Apoptotic cell death can be triggered by activation of extrinsic and intrinsic signaling pathways. Tumor necrosis factor (TNF)-related... 
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 3061 - 3061
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 2, pp. 496 - 505
Purpose: This study examined safety, pharmacokinetics, and efficacy of veliparib, a PARP inhibitor, combined with carboplatin and etoposide in patients with... 
TRIAL | SINGLE-AGENT | GERMLINE BRCA1 | ABT-888 | PLUS CARBOPLATIN | OVARIAN-CANCER | DNA-REPAIR | COMBINATION | CHEMOTHERAPY | PARP INHIBITOR VELIPARIB | ONCOLOGY | Index Medicus
Journal Article
01/2012, ISBN 1267379154
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults for which overall prognosis remains poor despite recent treatment... 
Pharmacy sciences | Oncology | Chemotherapy | Pharmacology | Kinetics | Cancer
Dissertation